A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer
(Q33340265)
scientific article published on December 1, 2001
scientific article published on December 1, 2001
Language: